In conclusion, our study elucidates a novel TTC36/YBX3/SPRED1/Ras/MAPK regulatory axis in HCC, highlighting TTC36 as a promising therapeutic target and prognostic marker. This evidence concerns the gene SPRED1 and hepatocellular carcinoma.